Drug Approval | May 08, 2025
Lupin launches Eslicarbazepine Acetate tablets in US
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Bayer expects 2025 to be the most difficult year of its turnaround
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Subscribe To Our Newsletter & Stay Updated
